Please login to the form below

Not currently logged in
Email:
Password:

lixisenatide

This page shows the latest lixisenatide news and features for those working in and with pharma, biotech and healthcare.

Sanofi wins EU approval for new diabetes combination Suliqua

Sanofi wins EU approval for new diabetes combination Suliqua

The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is

Latest news

More from news
Approximately 12 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Interview: Pierre Chancel, Sanofi Diabetes Interview: Pierre Chancel, Sanofi Diabetes

    Key among these for Sanofi is Lyxumia (lixisenatide), the company's new GLP-1 receptor agonist, which is planned for first launch in Germany following European approval and has been accepted

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics